Home > > > > > Report Detail

Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies

Publisher Name :
Date: 01-Dec-2015
No. of pages: 65

Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative.  Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy.  US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH.

NASH is the progressive form of Non-Alcoholic Fatty Liver Disease – NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patient's liver to harden and failure to work properly.  It is estimated that NASH affects 2 to 5% of the US population.  Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease.  Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty.  In Japan, the prevalence of NASH is rising although the population is not typically overweight.  Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities.

As per the US Association of Liver Disease, of those who develop NASH, ~15-25% will progress to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years.  Today, 1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden of this on US is over ~$5 billion per year.  Only new treatments in NASH could lead to a cut in this major cost burden along with improving quality of life.

Since a new innovation in NASH has been enlightened, the interest in companies developing drugs for NASH has also gone up.  In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharma’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver Diseases.  Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered into an exclusive agreement for the pipeline products which are being developed for NASH with a potential deal value of ~$450-600mn.

This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. This report list all the drugs in clinical trial and their design and the population recruited, also tells about the pathways representing possible targets for the treatment of NASH.

Companies Mentioned


  • Intercept Pharmaceuticals/ Dainippon Sumitomo,

  • Genfit,

  • Gilead,

  • Conatus Pharmaceuticals,

  • Galmed Pharmaceuticals,

  • Tobira Therapeutics,

  • Immuron,

  • Galectin Therapeutics,

  • Galecto Biotech,

  • Shire,

  • Boehringer Ingelheim,

  • Islet Sciences/BHV pharma,

  • Cadila Healthcare,

  • Novo Nordisk,

Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies

Table of Contents

Chapters Title

1. Executive Summary

2. Overview of NASH
2.1 Possible targets for the treatment of NASH
2.2 Drugs in the pipeline
2.3 Key Milestones
2.4 Drivers of M&A/ Licensing deals in NASH
2.5 NASH disease market opportunity to 2025

3. Products in Development and Competitive Landscape
3.1 Key Drugs/Companies Developing Drugs Against NASH
3.1.1 Obeticholic Acid – Intercept Pharmaceuticals/ Dainippon Sumitomo
3.1.2 Elafibranor – Genfit
3.1.3 Multiple programs – Gilead
3.1.4 Emricasan – Conatus Pharmaceuticals
3.1.5 Aramchol – Galmed Pharmaceuticals
3.1.6 Cenicriviroc – Tobira Therapeutics
3.1.7 IMM-124E – Immuron
3.1.8 GR-MD-02 – Galectin Therapeutics
3.1.9 TD139 - Galecto Biotech
3.1.10 SHP626 – Shire
3.1.11 PXS4728A – Boehringer Ingelheim
3.2 Repurposed Drugs for NASH
3.2.1 Remogliflozin etabonate - Islet Sciences/BHV pharma
3.2.2 Lipaglyn (saroglitazar) - Cadila Healthcare
3.2.3 Victoza (liraglutide) - Novo Nordisk

4. NASH – Etiology, Pathogenesis, Diagnosis and Current Treatment
4.1 Cause, Symptoms, Pathogenesis, Diagnosis
4.2 Current treatment including Herbal Medicine

5. Regulatory Pathway
5.1 Challenges in trials using endpoints to define clinically meaningful benefits
5.2 Potential Clinical Trial Design for NASH and Endpoints

6. Annexure

List of Tables

1 Nonalcoholic steatohepatitis: Ongoing clinical trials
2 Pathways representing possible targets for the treatment of NASH
3 Drugs in Development
4 Failed/ Discontinued drugs
5 Select deals in the field of NASH
6 Potential licensing/ M&A opportunities
7 Drugs in development for NASH and Target
8 Noninvasive diagnostic methods for NAFLD
9 PIVENS trial: Primary outcomes after 96 weeks of treatment
10 PIVENS trial: Secondary outcomes after 96 weeks of treatment
11 PIVENS trial: Safety outcomes after 96 weeks of treatment
12-14 NASH disease market opportunity to 2025 in US, Europe, and Japan

List of Figures

1 Putative mechanisms underlying the contribution of NAFLD
2 Progression of NAFLD to NASH
3 Various modes of FXR gene regulation
4 Elafibranor: Mechanism of Action
5 Comparison GOLDEN/ FLINT/ PIVENS: Efficacy in the NAS > 4 Phase III target population
6 A. GOLDEN-505: Cardio-Metabolic protection
B. GOLDEN-505: Glycemic parameters in diabetics
7 Simtuzumab: LOXL2 pathway
8 GS-4997: ASK1 in insulin resistance
9 Emricasan: Phase II data @ EASL 2015
10 Emricasan: Phase II data @ AASLD 2015
11 Aramchol: Phase IIa data – relative change in liver-fat concentration
12 Cenicriviroc (CVC): A potent inhibitor of infiltration of pro-inflammatory monocytes
13 Cenicriviroc (CVC): Lipid Profile – Changes from Baseline
14 Results from PhI/IIa trial: Efficacy of IMM-124E
15 GR-MD-02: PhI study – Serum Biomarkers Evaluation
16 GR-MD-02: Preclinical data – Tx effect on NASH with fibrosis
17 LEAN study: Schematic of the trial design
18 Forms of fatty liver disease
19 Pivotal role of activated Kupffer cells in the pathogenesis of NASH and fibrogenesis
20 Companion diagnostics: The potential endpoints
21 Polyherbal therapeutic approaches available for the management of NASH

  • Global Hepatitis A Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 89
    According to our LPI (LP Information) latest study, the global Hepatitis A Vaccine market size was valued at US$ 690.5 million in 2023. With growing demand in downstream market, the Hepatitis A Vaccine is forecast to a readjusted size of US$ 810.9 million by 2030 with a CAGR of 2.3% during review period. The research report highlights the growth potential of the global Hepatitis A Vaccine market. Hepatitis A Vaccine are expected to show stable growth in the future market. However, produc......
  • Global Human Hepatitis B Immunoglobulin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 127
    Market Overview of Global Human Hepatitis B Immunoglobulin market: According to our latest research, the global Human Hepatitis B Immunoglobulin market looks promising in the next 5 years. As of 2022, the global Human Hepatitis B Immunoglobulin market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensiv......
  • Global Hepatitis A Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 85
    According to our (Global Info Research) latest study, the global Hepatitis A Vaccine market size was valued at USD 726.3 million in 2023 and is forecast to a readjusted size of USD 842.5 million by 2030 with a CAGR of 2.1% during review period. Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currentl......
  • Global Hepatitis A Vaccine Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 117
    Report Overview: Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 ye......
  • Global Thymosin a1 Professional Survey Report 2023, Forecast to 2028
    Published: 15-Nov-2023        Price: US 3280 Onwards        Pages: 103
    Thymosin ?? is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene. It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their ......
  • Global Thymosin a1 Market Research Report 2023, Forecast to 2028
    Published: 15-Nov-2023        Price: US 2680 Onwards        Pages: 136
    Thymosin ?? is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene. It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their ......
  • Global Hepatitis B Immune Globulin Market Research Report 2023
    Published: 06-Nov-2023        Price: US 2900 Onwards        Pages: 85
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hepatitis B Immune Globulin market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - ADMA Biologics - Bio Products Laboratory - Grifols - Biotest AG - CSL Behring - FFF Enterprises - Cleveland Clinic Seg......
  • Global Sofosbuvir Market Research Report 2023
    Published: 31-Oct-2023        Price: US 2900 Onwards        Pages: 94
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Sofosbuvir market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Teva Pharmaceutical Industries Ltd - DONG BANG FUTURE TECH & LIFE CO., LTD - Beaukev Pharma International Pvt.Ltd - DEAFARMA - Tecoland - Anhui HaiKang Pha......
  • Global Hepatitis A Vaccine Market Insights, Forecast to 2029
    Published: 22-Sep-2023        Price: US 4900 Onwards        Pages: 97
    Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs